-
October 4, 2024 Lupin Acquires Nine Brands of Medical Nutritional Institute in South Africa
-
September 30, 2024 Lupin and Scope Sign a Distribution Agreement for the Commercialization of Optase® Range of Products in Mexico
-
September 27, 2024 Lupin Signs Distribution Agreement with Celnova for Orphan Drug NaMuscla®
-
September 18, 2024 Lupin Receives Approval from U.S. FDA for Bumetanide Injection, USP
-
September 18, 2024 Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India
-
September 4, 2024 Lupin Launches Mirabegron Extended-Release Tablets in the United States
-
August 29, 2024 Lupin Launches Doxorubicin Hydrochloride Liposome Injection in the United States
-
August 27, 2024 Lupin Receives Approval from U.S. FDA for Brimonidine Tartrate Ophthalmic Solution, 0.1%
-
August 23, 2024 Lupin Receives Health Canada Approval for Biosimilar Pegfilgrastim
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications